Review of Heterocyclic Frameworks for Antidiabetic Drugs, 2020–2024

A review document analyzing heterocyclic frameworks developed between 2020 and 2024 for antidiabetic drug discovery. The 2.1 MB DOCX file, authored by Sumit Tahlan and last updated in April 2026, highlights structure-activity relationships, molecular docking insights, and therapeutic mechanisms for various scaffold classes.

Use Cases

• Identify promising heterocyclic scaffolds for antidiabetic targets based on reported IC50 values and SAR insights.
• Analyze the impact of electron-donating groups and halogen substitutions on binding affinity and metabolic stability.
• Explore multi-target and hybrid molecule strategies for designing next-generation antidiabetic agents.
• Review emerging frontiers like multi-agonist therapies and AI-driven drug design mentioned in the document.

Strengths

• Focuses on a defined 2020–2024 timeframe for recent developments.
• Cites specific potency ranges, such as IC50 values from 1.20–22.46 µg/mL for dual α-amylase/α-glucosidase inhibitors.
• Discusses multiple scaffold classes (e.g., benzimidazoles, thiazolidinediones) and their therapeutic mechanisms.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 2.1 MB file size suggests a small-scale text document rather than a large structured dataset.

Provenance

Source

figshare, author Sumit Tahlan.

Collection Method

Likely a literature review and synthesis.

Time Range

2020–2024

Freshness

Last updated 2026-04-20 07:42:42; freshness should be verified.

Geography

null